Compositions of a polyorthoester and an aprotic solvent

Patent metadata

Field	Value
Publication number	US-10398686-B2
Application number	US-201715457545-A
Country	US
Kind code	B2
Filing date	Mar 13, 2017
Priority date	Mar 15, 2013
Publication date	Sep 3, 2019
Grant date	Sep 3, 2019

Abstract

Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.

First claim

What is claimed is:

1. A delivery system, comprising:
a polyorthoester;
dimethyl sulfoxide in which the polyorthoester is miscible to form a single phase; and
bupivacaine dispersed or solubilized in the single phase;
wherein the polyorthoester is a polyorthoester of Formula III;

where
A is R 1 or R 3 ,
R* is C1-4 alkyl,
n ranges from 5 to 1000,
R 1 is:

p and q are integers that vary from between about 1 to 20 and the average number of p or the average of the sum of p and q is between 1 and 7;
R 3 and R 6 are each independently:

x is an integer of 0-10;
R 5 is H or methyl, and

the fraction of A units that are of formula R 1 is between 0 and 25 mole percent.

2. The delivery system of claim 1 , wherein bupivacaine is dispersed in the single phase.

3. The delivery system of claim 1 , wherein bupivacaine is solubilized in the single phase.

4. The delivery system of claim 1 , wherein the delivery system has a viscosity of less than about 10,000 cP at 37° C.

5. The delivery system of claim 1 , where the polyorthoester has a molecular weight between about 1,000 and 10,000 daltons.

6. The delivery system of claim 1 , wherein bupivacaine is in an amount of about 1-20 percent by weight of the delivery system.

7. The delivery system of claim 6 , wherein bupivacaine is in an amount of about 2-5 percent by weight of the delivery system.

8. The delivery system of claim 1 , wherein dimethyl sulfoxide is in an amount of about 10-60 percent by weight of the delivery system.

9. The delivery system of claim 8 , wherein dimethyl sulfoxide is in an amount of about 10-20 percent by weight of the delivery system.

10. The delivery system of claim 1 , wherein the polyorthoester is in an amount of about 50-80 percent by weight of the delivery system.

Assignees

• Heron Therapeutics Inc

Inventors

• Ottoboni Thomas B
• Girotti Lee Ann Lynn

Classifications

• A61P23/02

  Local anaesthetics · CPC title

• A61P1/12

  Antidiarrhoeals · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K9/08

  Solutions {(composition of solutions A61K47/00)} · CPC title

• A61K31/4458 Primary

  only substituted in position 2, e.g. methylphenidate · CPC title